Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Restrictive Use of Dexamethasone in Glioblastoma

NCT04266977 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT04266977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04266977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Restrictive Use of Dexamethasone in Glioblastoma
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Not applicable
Overall status
Recruiting
Start date
May 8, 2020
Completion date
April 30, 2028
Enrollment
50 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

dexamethasone, glioblastoma, steroids